Drug Database
Back to search

France· FR:64606555

SYNACTHENE 0,25 mg/1 ml, solution injectable

A tetracosactide product containing tétracosactide, registered in France by ALFASIGMA (ITALIE), on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC H01AA02

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedSYNACTHENE 0,25 mg/1 ml, solution inj…ATCH01AA02REGISTER NO.FR:64606555PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about tétracosactideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tetracosactide is registered in 10 of 19 countries.

Countries holding a registration under ATC H01AA02 (tetracosactide), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 5 of them publish a price we can compare per daily dose
Search tetracosactide products by name

Tetracosactide · ATC H01AA02

10 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Franceprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
TÉTRACOSACTIDE
Manufacturer
ALFASIGMA (ITALIE)
Country
France (FR)
ATC code
H01AA02
ATC class
Tetracosactide
Defined daily dose
0.25 mg, P
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400931828693
    1 ampoule(s) en verre de 1 ml
    EUR 7.44

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

295 interactions on record for tetracosactide.

Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check tetracosactide against other medicinesHow interaction checks work

Tetracosactide · interactions on record

295 records

  • 29 severe
  • 246 moderate
  • 20 minor

Most severe, free to view

  • DesirudinB01AE01severe
  • Magnesium hydroxideA02AA04moderate
  • Kombinationen von AluminiumsalzenA02AB10moderate
  • Liquid paraffinA06AA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Tetracosactide in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tetracosactide products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

  • Austria · Synacthen Ampulle, Synacthen Depot
  • Belgium · Synacthen, Synacthen Depot
  • Denmark · Synacthen
  • Ireland · Synacthen
  • Italy · Synacthen
  • Luxembourg · Synacthen, Synacthen Dépôt
  • Netherlands · Synacthen
  • Sweden · Synacthen, Synacthen Depot

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ba167816-af2d-4448-a8ad-66d301e9fa52
GET /v1/drugs/ba167816-af2d-4448-a8ad-66d301e9fa52?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "64606555",
  "date_amm": "1998-08-04",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "TÉTRACOSACTIDE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "intramusculaire;intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about tetracosactide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console